Terapia de Vibración Focal con Dispositivo Vestible sobre la Función de la Extremidad Superior en Personas con Esclerosis Múltiple: Un Estudio Piloto
Viabilidad, Eficacia Preliminar y Perspectiva del Usuario sobre la Usabilidad de la Terapia de Vibración Focal Portátil en la Función de la Extremidad Superior de Personas con Esclerosis Múltiple: Un Estudio Piloto
This pilot mixed-method study will evaluate the feasibility, preliminary efficacy, and user experience of a home-based wearable Focal Vibration Therapy (FVT) intervention for improving upper extremity (UEx) function in people with multiple sclerosis (MS). Fifteen adults with relapsing-remitting MS (PRMS) and self-reported UEx impairments will participate in a 4-week FVT program using MyovoltTM wearable FVT devices applied to arm muscles.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Hongwu Wang, PhD
- Número de teléfono: 352-273-9934
- Correo electrónico: hongwu.wang@ufl.edu
Ubicaciones de estudio
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- Reclutamiento
- University of Florida
-
Contacto:
- Hongwu Wang, PhD
- Número de teléfono: 352-273-8433 352-273-9934
- Correo electrónico: hongwu.wang@ufl.edu
-
Gainesville, Florida, Estados Unidos, 32608
- Reclutamiento
- Norman Fixel Institute for Neurological Diseases
-
Contacto:
- Yun Chan Shin
- Número de teléfono: 352-273-8433
- Correo electrónico: yunchan.shin@ufl.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged over 18 years
- Confirmed diagnosis of RRMS according to the McDonald criteria (33)
- No MS relapse or exacerbation within the past 6 months (ensuring stability of symptoms)
- Self-report on clinical evidence of UEx impairment (including reduced arm/hand function, muscle weakness, spasticity, or pain).
- Stable on MS treatment for at least four weeks before recruitment, with no plans to initiate new treatments (participants may continue current treatments during the study)
- Agree and are able to use the FVT device after training.
- Sufficient proficiency in English to participate in interviews and follow instructions
- Able to visit the laboratory for assessments
- Able to provide written informed consent
Exclusion Criteria:
- Evidence of cognitive impairment that could interfere with following instructions (Mini-Montreal Cognitive Assessment score (Mini-MoCA) < 12)
- Comorbid neurological or psychiatric conditions affecting the UEx (including stroke and severe carpal tunnel syndrome) that would confound results or make FVT unsafe
- Unstable cardiac disease or any major medical illness that would preclude participation
- Any known contraindications to vibration therapy (pregnancy, acute deep vein thrombosis, severe osteoporosis, chronic migraines, epilepsy, active malignancy in the target area, unstable cardiac disease, or an implanted pacemaker without clearance)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Viabilidad del dispositivo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Intervention group
Participants who will recieve the focal vibration therapy |
The focal vibration intervention will be delivered using a modified MyoVolt wearable vibration therapy device. Each MyoVolt vibration device will be assigned to a single participant for individual use only and will be clearly labeled with a unique study ID. Devices will be distributed during the baseline training session and returned at the end of the study. To prevent unauthorized use:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Nine-Hole Peg Test (9HPT)
Periodo de tiempo: Baseline, week 4, week 8
|
The Nine-Hole Peg Test (9HPT) assesses fine motor coordination and dexterity by timing how quickly participants can place and remove nine pegs from a pegboard using one hand. |
Baseline, week 4, week 8
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Arm Function in Multiple Sclerosis Questionnaire (AMSQ)
Periodo de tiempo: Baseline, week 4, week 8
|
AMSQ is a 31-item MS-specific patient-reported outcome measure assessing arm and hand function. |
Baseline, week 4, week 8
|
|
Box and Block Test (BBT)
Periodo de tiempo: Baseline, week 4, week 8
|
The Box and Block Test (BBT) measures gross motor function with high test-retest reliability by counting the number of blocks a participant can transfer over a partition from one compartment to another within 60 seconds. |
Baseline, week 4, week 8
|
|
Muscle Strength
Periodo de tiempo: Baseline, week 4, week 8
|
Muscle strength will be evaluated using a handheld dynamometer. For grip strength assessment, participants will be seated with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, and the forearm and wrist in a neutral position. They will be instructed to squeeze the dynamometer with maximal effort for 3 seconds. Elbow flexion and extension strength will be assessed by applying the dynamometer to the distal part of the forearm as the participant resists the examiner's force for 3 seconds. The highest value from three trials in each arm and strength will be recorded and 60 seconds of recovery time will be applied between trials. |
Baseline, week 4, week 8
|
|
Modified Ashworth Scale (MAS)
Periodo de tiempo: Baseline, week 4, week 8
|
The Modified Ashworth Scale (MAS) is a widely used tool that assesses spasticity by measuring resistance during passive muscle stretching, graded on a scale from 0 (no increase in muscle tone) to 4 (rigid in flexion or extension) . |
Baseline, week 4, week 8
|
|
Visual Analog Scale (VAS) of Pain
Periodo de tiempo: Baseline, week 4, week 8
|
Subjective pain intensity will be measured by VAS on a scale from 0, indicating "no pain," to 10, indicating "worst possible pain". Participants will be asked about their neuropathic extremity pain in the UEx (manifesting as burning, tingling, and/or stabbing sensations), as well as pain caused by spasticity in the UEx (such as muscle stiffness or cramping). They will also be asked about instances where neuropathic pain occurs due to nonpainful stimulation such as light touch or non-extreme temperatures. Participants will rate their current UEx pain intensity, as well as the average level of UEx pain experienced over the past two weeks. Additionally, to evaluate how UEx pain has impacted their daily activities during the same period, participants will answer a modified question derived from the Chronic Pain Grade Scale. |
Baseline, week 4, week 8
|
|
Modified Fatigue Impact Scale (MFIS)
Periodo de tiempo: Baseline, week 4, week 8
|
MFIS is a validated self-report questionnaire designed to evaluate the perceived impact of fatigue in people with MS. The MFIS consists of 21 items, including 9 physical, 10 cognitive, and 2 psychosocial subscale items, and assesses fatigue experienced over the past 4 weeks. |
Baseline, week 4, week 8
|
|
Usability
Periodo de tiempo: week 4, week 8
|
Semi-structured interviews will be conducted with participants to explore their experiences with FVT after the post-intervention assessment and follow-up assessment. Each interview will be one-on-one, conducted by a single researcher. An open-ended interview guide will be developed to direct the conversation, covering domains of usability, acceptability, and perceived benefit of FVT. |
week 4, week 8
|
|
Adherence
Periodo de tiempo: week 4
|
Adherence to the 4-week FVT intervention will be tracked using multiple methods to ensure accuracy. Each participant will use the MyoVolt smartphone app, which automatically logs session attendance (date, time, intensity, and duration of each FVT session). The app data provides an objective record of when the device is activated. The MyoVolt app's built-in monitoring will serve as the primary source of adherence data. Participants will also fill out a simple daily adherence log immediately after each session. In this log, they will record the date and time of the session, the muscle sites stimulated (e.g., wrist extensors, biceps). This self-report acts as a cross-check against the app data and captures which muscle groups were targeted each day. Participants will be provided with a printed log template with spaces to fill in each field for every day of the 4-week intervention. This log will be collected at the post-intervention visit. |
week 4
|
|
Retention rate
Periodo de tiempo: baseline, week 4, week 8
|
Retention will be assessed by recording which participants complete the intervention and all outcome assessments. A retention log will note the status of each participant (Completed, Dropped Early, Lost to Follow-Up) and the reasons for drop-out. |
baseline, week 4, week 8
|
|
Adverse events
Periodo de tiempo: week 4, week 8
|
Participant safety will be closely monitored throughout the study. Adverse event documentation guidelines in the Agency for Healthcare Research and Quality manual were adopted. Participants will receive comprehensive information on adverse events and will be provided with diaries to record any occurrences, along with the contact information of the researcher. If an adverse event occurs, participants are instructed to immediately stop applying for FVT and contact the research team. |
week 4, week 8
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Hongwu Wang, University of Florida
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- IRB202500995
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This study will collect data from a research lab and home environment. Demographics, patient-reported and clinician-performed outcome assessments on upper extremity function, and technology-based vibration dosage and usage data will be acquired from 15 participants with multiple sclerosis both in-person and remotely. Identifiable data will be de-identified prior to repository submission. The study protocol, data collection forms/case report forms, data dictionary, manual of operations, and a glossary of domain-specific terms will be submitted. Participant age, sex, ethnicity, height, weight, socioeconomic status, medication usage, upper extremity motor fuction, gross motion fuction, strength, spasticity, and pain data will be collected and shared.
Marco de tiempo para compartir IPD
Scientific data will be shared as soon as possible. Scientific data included in published manuscripts will be available at the time of publication; all other generated scientific data will be shared no later than the end of the study. The study data will be stored in the public repository for at least 5 years.
Criterios de acceso compartido de IPD
Data will be stored in the UF system and sharing of de-identified data will be possible using a public repository such as the Institutional Repository at UF, as recommended by the UF Smathers Libraries Data Curation and Working Group. The study data will also be submitted to two generalist repositories participating in the NIH Generalist Repository Ecosystem Initiative, Synapse (for the wearable data) and Vivli. We will use the National Institute of Child Health and Human Development (NICHD) DASH (data and specimen hub) for repository. To promote the discoverability of the data, we will prepare a statement regarding data sharing and access to disseminate with presentations, publications, and public events related to this work. We will also submit metadata associated with the datasets to Synapse and Vivli. The repositories will provide metadata, persistent identifiers, and long-term access for open and controlled access.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .